• NeuroSense Therapeutics received a Japanese patent grant covering PrimeC, its lead oral drug candidate for amyotrophic lateral sclerosis.
• The patent covers a ciprofloxacin-celecoxib composition, including the formulation and manufacturing process, with protection running through 2042.
• The company is preparing to start a Phase 3 PARAGON trial in ALS following FDA clearance, targeting enrollment of about 300 participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606090900PR_NEWS_USPR_____IO79218) on June 09, 2026, and is solely responsible for the information contained therein.